<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976375</url>
  </required_header>
  <id_info>
    <org_study_id>7902-008</org_study_id>
    <secondary_id>MK-7902-008</secondary_id>
    <secondary_id>LEAP-008</secondary_id>
    <secondary_id>2018-003791-12</secondary_id>
    <secondary_id>E7080-G000-316</secondary_id>
    <secondary_id>195003</secondary_id>
    <nct_id>NCT03976375</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib
      (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer
      (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with
      one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are
      that pembrolizumab + lenvatinib (compared with docetaxel) prolongs: 1) overall survival (OS);
      and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version
      1.1 (RECIST 1.1) based on blinded independent central review (BICR).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2019</start_date>
  <completion_date type="Anticipated">February 23, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to ~48 months</time_frame>
    <description>OS is defined as the time from randomization to the date of death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to ~36 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. PFS will be assessed by blinded independent central review (BICR) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Docetaxel</measure>
    <time_frame>Up to ~18 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). ORR will be assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Lenvatinib Monotherapy</measure>
    <time_frame>Up to ~36 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). ORR will be assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to ~48 months</time_frame>
    <description>DOR is defined as the time from first documented evidence of Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) until disease progression or death due to any cause, whichever occurs first. DOR will be assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to ~48 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing Study Treatment Due to an AE</measure>
    <time_frame>Up to ~48 months</time_frame>
    <description>The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 &amp; 30) Scale Combined Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the quality of life (QoL) of cancer patients, including a combined global health status (GHS)/QoL (Items 29 and 30) scale. For each item, scores range from 0-100, with higher scores indicating higher GHS/QoL. Per protocol, scores for items 29 and 30 will be averaged to compute a combined GHS/QoL scale score. Change from baseline in the combined GHS/QoL scale score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 31) Scale Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31). For this item, individual responses to the question &quot;How much did you cough?&quot; are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 cough (Item 31) scale score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for chest pain (Item 40). For this item, individual responses to the question &quot;Have you had pain in your chest?&quot; are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 chest pain (Item 40) scale score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8). For this item, individual responses to the question &quot;Were you short of breath?&quot; are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 dyspnea (Item 8) scale score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a physical functioning (PF) scale (Items 1 to 5). The PF scale consists of participant responses to 5 questions regarding performance of daily activities [1) strenuous activities; 2) long walks; 3) short walks; 4) bed/chair rest; and 5) needing help with eating, dressing, washing themselves or using the toilet]. Overall PF scores range from 0 to 100, with a lower score indicating a better outcome. The change from Baseline in the EORTC QLQ-C30 PF (Items 1 to 5) scale combined score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status / Quality of Life (Items 29 &amp; 30) Scale Combined Score</measure>
    <time_frame>Up to ~48 months</time_frame>
    <description>The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a combined GHS/QoL (Items 29 and 30) scale. The TTD in the combined GHS/QoL (Items 29 &amp; 30) scale combined score will be presented, defined as the time to first onset of a ≥10 point decrease from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score</measure>
    <time_frame>Up to ~48 months</time_frame>
    <description>Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31). The TTD in EORTC QLQ-LC13 cough (Item 31) scale score will be presented, defined as the time to first onset of a ≥10 point decrease from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score</measure>
    <time_frame>Up to ~48 months</time_frame>
    <description>Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for chest pain (Item 40). The TTD in EORTC QLQ-LC13 chest pain (Item 40) scale score will be presented, defined as the time to first onset of a ≥10 point decrease from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score</measure>
    <time_frame>Up to ~48 months</time_frame>
    <description>The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8). The TTD in dyspnea (Item 8) scale score will be presented, defined as the time to first onset of a ≥10 point decrease from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to True Deterioration (TTD) in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score</measure>
    <time_frame>Up to ~48 months</time_frame>
    <description>The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a physical functioning (PF) scale (Items 1 to 5). The TTD in PF (Items 1 to 5) scale combined score will be presented, defined as the time to first onset of a ≥10 point decrease from baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">405</enrollment>
  <condition>Metastatic Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab at 200 mg, every 3 weeks (Q3W) via intravenous (IV) infusion on Day 1 of each 21-day cycle, in combination with lenvatinib at 20 mg, once daily (QD) via oral capsule. Pembrolizumab will be administered for up to 35 treatment cycles (~2 years). Lenvantinib will be administered until progressive disease or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive docetaxel at 75 mg/m^2, Q3W via IV infusion over 1-hour infusion on Day 1 of each 21-day cycle. Docetaxel will be administered until progressive disease or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenvatinib Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive lenvatinib at 24 mg, QD via oral capsule. Lenvantinib will be administered until progressive disease or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion of pembrolizumab at 200 mg</description>
    <arm_group_label>Pembrolizumab+Lenvatinib</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.</description>
    <arm_group_label>Lenvatinib Monotherapy</arm_group_label>
    <arm_group_label>Pembrolizumab+Lenvatinib</arm_group_label>
    <other_name>MK-7902</other_name>
    <other_name>E7080</other_name>
    <other_name>LENVIMA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>IV infusion of docetaxel at 75 mg/m^2.</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <other_name>TAXOTERE®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a histologically or cytologically confirmed diagnosis of metastatic squamous or
             nonsquamous NSCLC (Stage IV: M1a, M1b, M1c).

          -  Has PD on treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb)
             administered either as monotherapy or in combination with other checkpoint inhibitors
             or other therapies.

               -  Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall
                  course of treatment

          -  Has PD during/after platinum doublet chemotherapy for metastatic disease.

          -  Has confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as
             primary therapy.

          -  Has submitted pre-study imaging that confirmed evidence of PD following initiation of
             an anti-PD-1/PD-L1 inhibitor.

          -  Has at least 1 measurable lesion by computerized tomography (CT) or magnetic resonance
             imaging (MRI) per RECIST 1.1, as determined by the local site assessment.

          -  Has provided tumor tissue for PD-L1 biomarker analysis from an archival sample
             (defined as: from initial diagnosis of NSCLC and prior to receiving immunotherapy
             [antiPD-1/PD-L1], from the primary lesion or a metastatic lesion).

          -  Has provided prior to allocation tissue from a newly obtained formalin-fixed sample
             from a new biopsy (defined as: after completion of immunotherapy [anti-PD-1/PD-L1] and
             before receiving a randomization number), of a tumor lesion not previously irradiated.

          -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7
             days before the first dose of study intervention but before randomization.

          -  Has a life expectancy of at least 3 months.

          -  Male participants receiving pembrolizumab ± lenvatinib or lenvatinib must agree to
             refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse;
             or 2) follow contraceptive guidance during the treatment period or 30 days after the
             last dose of lenvatinib. Male participants receiving docetaxel agree to adhere to the
             same conditions during the treatment period and for ≥180 days after the last dose of
             study treatment.

          -  Female participants must be not pregnant, not breastfeeding, and not be a woman of
             child-bearing potential (WOCBP). If a WOCBP, agrees to not donate eggs and either use
             contraception, or be abstinent from heterosexual intercourse during the treatment
             period and for ≥120 days after the last dose of pembrolizumab or 30 days after the
             last dose of lenvatinib, whichever occurs first. If a WOCBP receiving docetaxel,
             agrees to adhere to the same conditions during the treatment period and for ≥180 days
             after the last dose of study treatment.

          -  Has adequately controlled blood pressure (BP) with or without antihypertensive
             medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications
             within 1 week before randomization.

          -  If participant received major surgery or radiation therapy of &gt;30 Gy, they have
             recovered from the toxicity and/or complications from the intervention.

          -  Has adequate organ function.

        Exclusion Criteria:

          -  Has received docetaxel as monotherapy or in combination with other therapies.

          -  Has received lenvatinib as monotherapy or in combination with an anti-PD-1/PD-L1 mAb.

          -  Has received: 1) radiotherapy within 2 weeks before the first dose of study treatment;
             or 2) lung radiation therapy &gt;30 Gy within 6 months before the first dose of study
             treatment.

          -  Has received a live vaccine within 30 days before the first dose of study treatment.

          -  Has clinically significant hemoptysis or tumor bleeding within 2 weeks before the
             first dose of study treatment.

          -  Has radiographic evidence of intratumoral cavitation, encasement, or invasion of a
             major blood vessel.

          -  Has clinically significant cardiovascular impairment within 12 months of the first
             dose of study treatment.

          -  Has a history of a gastrointestinal condition or procedure that may affect oral
             absorption of study treatment.

          -  Has a pre-existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.

          -  Is currently participating in a clinical trial and receiving study therapy or
             participated in a study of an investigational agent within 4 weeks of the first dose
             of study treatment.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             or any other form of immunosuppressive therapy within 7 days before the first dose of
             study treatment.

          -  Has a known history of an additional malignancy, except if the participant has
             undergone potentially curative therapy with no evidence of disease recurrence for 3
             years since initiation of that therapy.

          -  Has known active central nervous system metastases and/or carcinomatous meningitis.

          -  Has severe hypersensitivity to pembrolizumab and/or any of its excipients.

          -  Has a sensitivity to any of the excipients contained in lenvatinib and/or docetaxel.

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years.

          -  Has a history of (noninfectious) pneumonitis that required systemic steroids or
             current pneumonitis/interstitial lung disease.

          -  Has an active infection requiring systemic therapy.

          -  Has a known history of human immunodeficiency virus (HIV) infection.

          -  Has a known history of hepatitis B reactive or known active hepatitis C virus
             infection.

          -  Has active tuberculosis.

          -  Has a known psychiatric or substance abuse disorder that would interfere with the
             participant's ability to cooperate with the requirements of the study.

          -  Has a left ventricular ejection fraction (LVEF) below the institutional normal range.

          -  Has QT interval corrected with Fridericia's formula (QTcF) prolongation to &gt;480 msec.

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through at least
             120 days after the last dose of pembrolizumab or lenvatinib, or 180 days after the
             last dose of docetaxel.

          -  Has had an allogeneic tissue/solid organ transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Comprehensive Blood &amp; Cancer Center [Bakersfield, CA] ( Site 1604)</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>661-322-2206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid-Florida Cancer Centers ( Site 1611)</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>943-993-7578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky School of Medicine &amp; Hospitals ( Site 1621)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>859-218-6704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic ( Site 1680)</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>225-767-0822</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harry &amp; Jeanette Weinberg Cancer Institute ( Site 1626)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-777-7364</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medstar Good Samaritan Hospital ( Site 1625)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-444-4303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ( Site 1622)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-724-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MGH - North Shore Cancer Center ( Site 1668)</name>
      <address>
        <city>Danvers</city>
        <state>Massachusetts</state>
        <zip>01923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-724-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Billings Clinic ( Site 1631)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>406-435-7415</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bozeman Health Deaconness Cancer Center ( Site 1632)</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>406-414-4475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center At Basking Ridge ( Site 1664)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-4337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Middletown ( Site 1665)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-4337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Montvale ( Site 1667)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-4337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Commack ( Site 1662)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-4337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 1666)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-4337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center ( Site 1661)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-4337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester ( Site 1638)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>585-275-5823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center - Nassau ( Site 1670)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-4337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest ( Site 1644)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-335-6310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center ( Site 1647)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-728-2984</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Millenium Physicians ( Site 1690)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>877-870-2640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital ( Site 0004)</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61286705070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Port Macquarie Base Hospital ( Site 0003)</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61265801820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital ( Site 0005)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61288905200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care Centre ( Site 0001)</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61242286200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital - Division of Cancer Services ( Site 0002)</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61731766505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Calvary Central Districts Hospital ( Site 0007)</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61882825266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bendigo Cancer Centre ( Site 0008)</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <zip>3552</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61354548815</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba ( Site 1504)</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>2047872108</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre ( Site 1503)</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6135496666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program - London HSC ( Site 1505)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5196858618</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 1502)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4169464645</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 1501)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514-345-3511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rodrigo Botero SAS ( Site 1300)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050030</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5743490791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1305)</name>
      <address>
        <city>Valledupar</city>
        <state>Cesar</state>
        <zip>200002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573157411877</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica S.A. ( Site 1302)</name>
      <address>
        <city>Monteria</city>
        <state>Cordoba</state>
        <zip>230001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573158441430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Administradora Country SA - Clinica del Country ( Site 1307)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5715300470</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1304)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110311</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573017868271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco de Cali S.A ( Site 1301)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573155760189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Caen Service de Pneumologie ( Site 0401)</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33231064676</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Percy-Clamart ( Site 0411)</name>
      <address>
        <city>Clamart</city>
        <state>Hauts-de-Seine</state>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33141466267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Centre Paul Papin ( Site 0412)</name>
      <address>
        <city>Angers</city>
        <state>Maine-et-Loire</state>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33241352791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Ambroise Pare ( Site 0402)</name>
      <address>
        <city>Beuvry</city>
        <state>Pas-de-Calais</state>
        <zip>62620</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33321619270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General - Avignon ( Site 0407)</name>
      <address>
        <city>Avignon</city>
        <state>Provence-Alpes-Cote-d'Azur</state>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33432759330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans ( Site 0406)</name>
      <address>
        <city>Le Mans</city>
        <state>Sarthe</state>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33243432764</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie ( Site 0400)</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33144324606</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou ( Site 0408)</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33156092452</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera GmbH ( Site 0503)</name>
      <address>
        <city>Gera</city>
        <state>Thuringen</state>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493658282151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Spandau ( Site 0505)</name>
      <address>
        <city>Berlin</city>
        <zip>13585</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930130132601</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0601)</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36205374212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz ( Site 0609)</name>
      <address>
        <city>Gyor</city>
        <state>Gyor-Moson-Sopron</state>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3696418244</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0610)</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209323256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tudogyogyintezet Torokbalint ( Site 0602)</name>
      <address>
        <city>Torokbalint</city>
        <state>Pest</state>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3623511570258</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Tudogyogyintezet ( Site 0607)</name>
      <address>
        <city>Farkasgyepu</city>
        <state>Veszprem</state>
        <zip>8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3689358013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem.. ( Site 0604)</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3613559733</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Koranyi Pulmonologiai Intezet ( Site 0603)</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3613913200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Koranyi Pulmonologiai Intezet ( Site 0608)</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3613913228</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 0701)</name>
      <address>
        <city>Beer Sheva</city>
        <state>HaDarom</state>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972587040620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center ( Site 0702)</name>
      <address>
        <city>Kfar-Saba</city>
        <state>HaMerkaz</state>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97297472414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0700)</name>
      <address>
        <city>Petah Tikva</city>
        <state>HaMerkaz</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239378101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0703)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97248542811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 0704)</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tell Abib</state>
        <zip>5266202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235308495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center (Ichilov) - Oncology Clinic ( Site 0705)</name>
      <address>
        <city>Tel Aviv</city>
        <state>Tell Abib</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236973494</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo - ASST Monza ( Site 0804)</name>
      <address>
        <city>Monza</city>
        <state>Monza E Brianza</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390392339678</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 0807)</name>
      <address>
        <city>Rome</city>
        <state>Roma</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390652666919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luigi Gonzaga ( Site 0802)</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390119026978</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Giuseppe Moscati ( Site 0809)</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390825203573</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0808)</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390805555418</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Vittorio Emanuele ( Site 0811)</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390953782426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori ( Site 0806)</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223903813</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Villa Sofia - Cervello P.O. Villa Sofia ( Site 0810)</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393478837013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia ( Site 0805)</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393384569353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center ( Site 0105)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81457019581</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital ( Site 0107)</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81222226181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital ( Site 0104)</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81728040101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital ( Site 0106)</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81432227171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital ( Site 0101)</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81252665111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital ( Site 0103)</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335422511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR ( Site 0100)</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335200111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital ( Site 0201)</name>
      <address>
        <city>Cheongju si</city>
        <state>Chungcheongbuk-do [Chungbuk]</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82432696015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 0204)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82317877003</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0202)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222280512</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 0203)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230103215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte E.P.E. - Hospital Pulido Valente ( Site 1801)</name>
      <address>
        <city>Lisboa</city>
        <zip>1769-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351217548085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ad-Vance Medical Research LLC ( Site 2103)</name>
      <address>
        <city>Ponce</city>
        <zip>00717</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>7876516697</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puerto Rico Medical Research Center LLC ( Site 2101)</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>787-296-8394</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 0905)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74992635300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Administration of the President ( Site 0910)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74955300891</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omsk Clinical Oncology Dispensary ( Site 0913)</name>
      <address>
        <city>Omsk</city>
        <state>Omskaya Oblast'</state>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73812601037</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPb SBHI City Clinical Oncological Dispensary ( Site 0901)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219506526</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Railway Hospital of OJSC ( Site 0907)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79052154918</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0903)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79117500005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias ( Site 1002)</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34985106121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d Hebron ( Site 1004)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934894158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla ( Site 1003)</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34942202525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria ( Site 1011)</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961452191</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro ( Site 1007)</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34911917509</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid ( Site 1012)</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914521987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia ( Site 1010)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961973500436633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ciudad de Jaen ( Site 1000)</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34953220306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz ( Site 1005)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915504800253900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre ( Site 1006)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913908349</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consorci Hospitalari Mataro ( Site 1008)</name>
      <address>
        <city>Mataro</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary ( Site 1114)</name>
      <address>
        <city>Aberdeen</city>
        <state>Aberdeen City</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441224553500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hull &amp; East Yorkshire NHS Trust. Castle Hill Hospital ( Site 1108)</name>
      <address>
        <city>Cottingham</city>
        <state>East Riding Of Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441482461316</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary ( Site 1110)</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+447768493428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Middlesex University Hospital NHS Trust ( Site 1109)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442088872687</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy s and St Thomas Hospital NHS Foundation Trust ( Site 1102)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+447881825754</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre ( Site 1107)</name>
      <address>
        <city>Northwood</city>
        <state>London, City Of</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441438284298</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital Campus ( Site 1105)</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+44115969116959816</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital ( Site 1103)</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441214247456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry and Warwickshire NHS Trust ( Site 1112)</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442476967151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St James s University Hospital ( Site 1106)</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441132067951</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trial Information</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>programmed cell death 1 (PD-1, PD1)</keyword>
  <keyword>programmed cell death-ligand 1 (PD-L1, PDL1)</keyword>
  <keyword>programmed cell death-ligand 2 (PD-L2, PDL2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

